The combination of Opdivo and Yervoy is also approved for metastatic melanoma, first-line treatment of adult patients with metastatic non-small cell lung cancer, first-line treatment of adult ...

BMY obtains CHMP recommendation for Opdivo for perioperative regimen of neoadjuvant Opdivo and chemotherapy followed by ...

EMA committee recommends approval of Bristol Myers Squibb’s subcutaneous formulation of Opdivo across multiple solid tumour indications: Princeton, New Jersey Monday, March 31, ...

Opdivo was approved as a second-line monotherapy for melanoma in 2014 – its first-ever approval – and the duo with Yervoy was cleared a year later. Opdivo is also approved for adjuvant use on ...

This approval is grounded in the results from the Phase 3 CheckMate -9DW study, which indicated a notable improvement in overall survival for patients treated with the Opdivo plus Yervoy ...

Shares of BMY have risen 18% in the past year against the industry’s decline of 7%. The combination of Opdivo and Yervoy is also approved for metastatic melanoma, first-line treatment of adult ...

Bristol Myers BMY announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) has recommended approval of Opdivo (nivolumab ...

The first is an Opdivo and Yervoy combination for advanced melanoma, the first such immuno-oncology combination therapy approved. The second is for Emplicti, developed with AbbVie for multiple ...

Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines ...